Alyeska Investment Group, L.P. Cure Vac N.V. Transaction History
Alyeska Investment Group, L.P.
- $18 Billion
- Q3 2024
A detailed history of Alyeska Investment Group, L.P. transactions in Cure Vac N.V. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 400,000 shares of CVAC stock, worth $1.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
400,000Holding current value
$1.2 Million% of portfolio
0.01%Shares
4 transactions
Others Institutions Holding CVAC
# of Institutions
93Shares Held
12.3MCall Options Held
164KPut Options Held
117K-
Israel Englander Millennium Management LLC | New York, Ny2.42MShares$7.23 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.25MShares$6.74 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$4.69 Million10.6% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.01MShares$3.02 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct780KShares$2.33 Million0.01% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $561M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...